Abstract
Heparan sulfate that contains antithrombin binding sites is designated as anticoagulant heparan sulfate (HSact) since, in vitro, it dramatically enhances the neutralization of coagulation proteases by antithrombin. Endothelial cell production of HSact is controlled by the Hs3st1 gene, which encodes the rate limiting enzyme—heparan sulfate 3-O-sulfotransferase-1 (Hs3st1). It has long been proposed that levels of endothelial HSact may tightly regulate hemostatic tone. This potential in vivo role of HSact was assessed by generating Hs3st1 −/− knockout mice. Hs3st1 −/− and Hs3st1 +/+ mice were evaluated with a variety of methods, capable of detecting altered hemostatic tone. However, both genotypes were indistinguishable. Instead, Hs3st1 −/− mice exhibited lethality on a specific genetic background and also showed intrauterine growth retardation. Neither phenotypes result from a gross coagulopathy. So although this enzyme produces the majority of tissue HSact, Hs3st1 −/− mice do not show an obvious procoagulant phenotype. These results suggest that the bulk of HSact is not essential for normal hemostasis and that hemostatic tone is not tightly regulated by total levels of HSact. Moreover, the unanticipated non-thrombotic phenotypes suggest structure(s) derived from this enzyme might serve additional/alternative biologic roles. Published in 2003.
Similar content being viewed by others
References
Rosenberg RD, Lam L, Correlation between structure and function of heparin, Proc Natl Acad Sci USA 76, 1218–22 (1979).
Lindahl U, Bäckström G, Thunberg L, Leder IG, Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombinbinding sequence of heparin, Proc Natl Acad Sci USA 77, 6551–5 (1980).
Lindahl U, Bäckström G, Thunberg L, The antithrombin-binding sequence in heparin: Identification of an essential 6-O sulfate group, J Biol Chem 258, 9826–30 (1983).
Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G, Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity, Biochem Biophys Res Commun 116, 492–9 (1983).
Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J, Contribution of monosaccharide residues in heparin binding to antithrombin III, Biochemistry 24, 6723–9 (1985).
Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J, Contribution of 3-O-and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III, Biochemistry 26, 6454–61 (1987).
Zhang L, Yoshida K, Liu J, Rosenberg RD, Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells, J Biol Chem 274, 5681–91 (1999).
Damus PS, Hicks M, Rosenberg RD, Anticoagulant action of heparin, Nature 246, 355–7 (1973).
Marcum JA, McKenney JB, Galli SJ, Jackman RW, Rosenberg RD, Anticoagulantly active heparin-like molecules from mast celldeficient mice, Am J Physiol 250, H879–H88 (1986).
Marcum JA, McKenney JB, Rosenberg RD, The acceleration of thrombin-antithrombin complex formation in rat hindquarters via naturally occurring heparin-like molecules bound to the endothelium, J Clin Invest 74, 341–50 (1984).
van Boven HH, Lane DA, Antithrombin and its inherited deficiency states, Seminars in Hematology 34, 188–204 (1997).
Rosenberg RD, Vascular-bed-specific hemostasis and hypercoagulable states: Clinical utility of activation peptide assays in predicting thrombotic events in different clinical populations, Thromb Haemost 86, 41–50 (2001).
Marcum JA, Rosenberg RD, The biochemistry, cell biology, and pathophysiology of anticoagulantly active heparin-like molecules of the vessel wall. In Heparin, Chemical and Biological Properties: Clinical Applications, edited by Lane DA, Lindahl U (London, Edward Arnold, 1999), pp. 275–94.
de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD, Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta, J Cell Biol 111, 1293–304 (1990).
Thomas DP, Roberts HR, Hypercoagulability in venous and arterial thrombosis, Ann Intern Med 126, 638–44 (1997).
Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg RD, Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells, J Biol Chem 267, 4859–69 (1992).
Marcum JA, Rosenberg RD, Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells, Biochem Biophys Res Commun 126, 365–72 (1985).
Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD, Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan, J Biol Chem 261, 7507–17 (1986).
Shworak NW, Shirakawa M, Colliec-Jouault S, Liu J, Mulligan RC, Birinyi LK, Rosenberg RD, Pathway-specific regulation of the synthesis of anticoagulantly active heparan sulfate, J Biol Chem 269, 24941–52 (1994).
de Agostini AL, Lau HK, Leone C, Youssoufian H, Rosenberg RD, Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence, Proc Natl Acad Sci USA 87, 9784–8 (1990).
Colliec-Jouault S, Shworak NW, Liu J, de Agostini AI, Rosenberg RD, Characterization of a cell mutant specifically defective in the synthesis of anticoagulantly active heparan sulfate, J Biol Chem 269, 24953–8 (1994).
de Agostini AI, Watkins SC, Slater HS, Youssoufian H, Rosenberg RD, Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta, Journal of Cell Biology 111, 1293–304 (1990).
Kojima T, Shworak NW, Rosenberg RD, Molecular cloning and expression of two distinct cDNA encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line, J Biol Chem 267, 4870–7 (1992).
Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G, Cell surface heparan sulfate proteoglycans from human vascular Mice deficient in heparan sulfate 3-O-sulfotransferase-1 361 endothelial cells. Core protein characterization and antithrombin III binding properties, J Biol Chem 267, 20435–43 (1992).
Liu J, Shworak NW, Fritze LMS, Edelberg JM, Rosenberg RD, Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase, J Biol Chem 271, 27072–82 (1996).
Shworak NW, Liu J, Fritze LMS, Schwartz JJ, Zhang L, Logeart D, Rosenberg RD, Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase, J Biol Chem 272, 28008–19 (1997).
Shworak NW, Fritze LMS, Liu J, Butler LD, Rosenberg RD, Cellfree synthesis of anticoagulant heparan sulfate reveals a limiting activity which modifies a nonlimiting precursor pool, J Biol Chem 271, 27063–71 (1996).
Shworak NW, Liu J, Petros LM, Zhang L, Kobayashi M, Copeland NG, Jenkins NA, Rosenberg RD, Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci, J Biol Chem 274, 5170–84 (1999).
Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, Rosenberg RD, Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities, J Biol Chem 274, 5185–92 (1999).
Yabe T, Shukla D, Spear PG, Rosenberg RD, Seeberger PH, Shworak NW, Portable sulphotransferase domain determines sequence specificity of heparan sulphate 3-O-sulphotransferases, Biochem J 359, 235–41 (2001).
HajMohammadi S, Enjyoji K, Princivalle M, Christi P, Lech M, Beeler DL, Rayburn H, Schwartz JJ, Barzegar S, de Agostini AI, Post MJ, Rosenberg RD, Shworak NW, Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis, J Clin Invest in press (2003).
Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, Takeda N, Ito M, Yamamoto K, Matsushita T, Kusugami K, Muramatsu T, Saito H, Complete antithrombin deficiency in mice results in embryonic lethality, J Clin Invest 106, 873–8 (2000).
Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD, A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state, J Clin Invest 101, 1983–91 (1998).
Christie PD, Edelberg JM, Picard MH, Foulkes AS, Mamuya W, Weiler-Guettler H, Rubin RH, Gilbert P, Rosenberg RD, A murine model of myocardial microvascular thrombosis, J Clin Invest 104, 533–9 (1999).
Labarrere CA, Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation, Curr Opin Cardiol 14, 133–9 (1999).
Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, Kisiel W, Stern DM, Pinsky DJ, Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation, J Clin Invest 99, 1729–38 (1997).
Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D, Vitronectin inhibits the thrombotic response to arterial injury in mice, Blood 93, 1825–30 (1999).
Farrehi PM, Ozaki CK, Carmeliet P, Fay WP, Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice, Circulation 97, 1002–8 (1998).
Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI, Characterization of a mouse model for thrombomodulin deficiency, Arterioscler Thromb Vasc Biol 21, 1531–7 (2001).
Segel GB, Francis CA, Anticoagulant proteins in childhood venous and arterial thrombosis: A review, Blood Cells Mol Dis 26, 540–60 (2000).
Gandelman R, Simon NG, Spontaneous pup-killing by mice in response to large litters, Dev Psychobiol 11, 235–41 (1978).
Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB, Increased frequency of genetic thrombophilia in women with complications of pregnancy, N Engl J Med 340, 9–13 (1999).
Peeters LL, Thrombophilia and fetal growth restriction, Eur J Obstet Gynecol Reprod Biol 95, 202–5 (2001).
Evans MI, Schulman JD, Golden L, Mukherjee AB, Superovulation-induced intrauterine growth retardation in mice, Am J Obstet Gynecol 141, 433–5 (1981).
Bassan H, Trejo LL, Kariv N, Bassan M, Berger E, Fattal A, Gozes I, Harel S, Experimental intrauterine growth retardation alters renal development, Pediatr Nephrol 15, 192–5 (2000).
Lang U, Baker RS, Khoury J, Clark KE, Effects of chronic reduction in uterine blood flowon fetal and placental growth in the sheep, Am J Physiol Regul Integr Comp Physiol 279, R53–9 (2000).
Lin CC, Santolaya-Forgas J, Current concepts of fetal growth restriction: Part I. Causes, classification, and pathophysiology, Obstet Gynecol 92, 1044–55 (1998).
Redline RW, Pappin A, Fetal thrombotic vasculopathy: The clinical significance of extensive avascular villi, Hum Pathol 26, 80–5 (1995).
Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS, 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD, Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation, Nat Med 5, 1010–7 (1999).
Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D, Spontaneous thrombosis in mice carrying the factor V Leiden mutation, Blood 96, 4222–6 (2000).
Healy AM, Hancock WW, Christie PD, Rayburn HB, Rosenberg RD, Intravascular coagulation activation in a murine model of thrombomodulin deficiency: Effects of lesion size, age, and hypoxia on fibrin deposition, Blood 92, 4188–97 (1998).
Dewerchin M, Hérault J, Wallays G, Moons L, Stalmans I, Collen D, Carmeliet P, Herbert J, Life-threatening thrombosis in mice with targeted Arg47 to Cys mutation of the heparin binding domain of antithrombin, Circ 104(Suppl. 2), A109442 (2001).
Hosseini G, Liu J, de Agostini AI, Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells, J Biol Chem 271, 22090–9 (1996).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shworak, N.W., HajMohammadi, S., de Agostini, A.I. et al. Mice deficient in heparan sulfate 3-O-sulfotransferase-1: Normal hemostasis with unexpected perinatal phenotypes. Glycoconj J 19, 355–361 (2002). https://doi.org/10.1023/A:1025377206600
Issue Date:
DOI: https://doi.org/10.1023/A:1025377206600